Table 2.
Treatment efficacy compared with drug placebo
Number of trials (n=54)* | Number of patients (n=6652)* |
Mean YBOCS difference |
|||
---|---|---|---|---|---|
Full network (n=54) | Excluding waiting list controlled trials (n=48) | ||||
Drug placebo | 23 | 1515 | Reference | Reference | |
Waiting list | 6 | 97 | 5·62 (0·91 to 10·26) | NA | |
Psychological placebo† | 6 | 196 | −4·15 (−8·65 to 0·49) | −1·90 (−5·62 to 1·91) | |
SSRIs (class effect) | 37 | 3158 | −3·49 (−5·12 to −1·81) | −3·62 (−4·89 to −2·34) | |
Fluoxetine | 6 | 633 | −3·46 (−5·27 to −1·58) | −3·67 (−5·13 to −2·26) | |
Fluvoxamine | 13 | 521 | −3·60 (−5·29 to −1·95) | −3·66 (−4·96 to −2·37) | |
Paroxetine | 8 | 902 | −3·42 (−5·10 to −1·61) | −3·51 (−4·81 to −2·14) | |
Sertraline | 7 | 565 | −3·50 (−5·30 to −1·63) | −3·68 (−5·14 to −2·30) | |
Citalopram | 2 | 311 | −3·49 (−5·62 to −1·31) | −3·60 (−5·25 to −1·91) | |
Escitalopram | 1 | 226 | −3·48 (−5·61 to −1·23) | −3·59 (−5·25 to −1·86) | |
Venlafaxine | 2 | 98 | −3·22 (−8·26 to 1·88) | −3·21 (−7·01 to 0·69) | |
Clomipramine | 13 | 831 | −4·72 (−6·85 to −2·60) | −4·66 (−6·26 to −3·05) | |
BT† | 11 | 287 | −14·48 (−18·61 to −10·23) | −10·41 (−14·04 to −6·77) | |
CBT† | 9 | 231 | −5·37 (−9·10 to −1·63) | −7·98 (−11·02 to −4·93) | |
Cognitive therapy† | 6 | 172 | −13·36 (−18·40 to −8·21) | −9·45 (−13·76 to −5·19) | |
Hypericum | 1 | 30 | −0·15 (−7·46 to 7·12) | −0·13 (−5·93 to 5·68) | |
CBT and fluvoxamine | 1 | 6 | −7·50 (−13·89 to −1·17) | −8·81 (−13·75 to −3·88) | |
BT and clomipramine | 1 | 31 | −12·97 (−19·18 to −6·74) | −11·68 (−16·73 to −6·65) |
Data in parentheses are 95% credible intervals. YBOCS=Yale-Brown Obsessive Compulsive Scale. BT=behavioural therapy. CBT=cognitive behavioural therapy. NA=not applicable.
Individual trials could be included in more than one treatment category.
Several patients randomly allocated into these psychotherapeutic interventions were allowed to take stable doses of antidepressants and remain on the same dose without further adjustments.